News

Partner to entrepreneurs, innovators and businesses in their quest to realize their full potential

Image

January 22, 2024

Pi-Cardia Receives FDA Breakthrough Device Designation for ShortCut™

First dedicated leaflet modification device to enable TAVR in patients at risk of coronary obstruction

Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today it received Breakthrough Device Designation from the US Food and Drug Administration for ShortCut™ - the world's first dedicated leaflet modification device facilitating valve-invalve Transcatheter Aortic Valve Replacement (TAVR) procedures in patients at risk of coronary obstruction.
Learn More

October 26, 2023

Magenta Medical Reports Positive Results for US Early Feasibility Study of Elevate™ Heart Pump in Providing Temporary Mechanical Circulatory Support During High-Risk PCI Procedures

The US Early Feasibility Study of Magenta Medical's Elevate™ System, designed to provide temporary mechanical circulatory support during high-risk percutaneous coronary intervention (HR-PCI) procedures, has successfully met its objectives. Elevate™ is the smallest and most powerful percutaneous Left Ventricular Assist Device (pLVAD) in the world.
Learn More

September 30, 2023

Pi-Cardia Successfully Completes Enrollment in Pivotal Study for ShortCut™

Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today the successful completion of its ShortCut™ Pivotal Study enrollment. ShortCut™ is the world's first dedicated device designed to split the leaflets of pre-existing valves to enable safe Transcatheter Aortic Valve Replacement (TAVR) in patients at risk of coronary obstruction.
Learn More

August 23, 2023

Trisol announces successful implants of its Transcatheter Tricuspid Valve in the US

The heart teams at the Piedmont Heart Institute in Atlanta, Georgia, USA and the University of Virginia Health System in Charlottesville, VA, USA, successfully performed the first two implantations in the US of the Trisol Transcatheter Tricuspid Valve Replacement as part of a U.S. Food and Drug Administration approved Early Feasibility Study (EFS), led by Principal Investigator Isaac George, MD.
Learn More

May 03, 2023

Magenta Medical Closes $55M Funding Round Led by OrbiMed

Magenta Medical, developer of the world's smallest heart pump, announced today a $55M financing round led by global healthcare investment manager OrbiMed, with participation from existing investors New Enterprise Associates (NEA), Pitango VC, and ALIVE - Israel HealthTech Fund. The financing will be used, among other things, to advance the clinical programs of the company's product in the United States towards its first FDA approval.
Learn More

December 9, 2022

Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.
Learn More

November 30, 2022

Ferring Receives U.S. FDA Approval for REBYOTA™ (fecal microbiota, live-jslm) – A Novel First-in-Class Microbiota-Based Live Biotherapeutic

Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTA™ (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.
Learn More

November 23, 2022

NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease Patients

NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS or “NewAmsterdam” or the “Company”), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced the closing of its business combination with Frazier Lifesciences Acquisition Corporation (Nasdaq:FLAC), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners.
Learn More

September 2, 2022

Aker BioMarine enters Lysoveta agreement with Trofi Nutritionals

Aker BioMarine has signed a commercial agreement to develop several medical foods products based on the existing Lysoveta, with Trofi Nutritionals.
Learn More

July 26, 2022

Pi-Cardia Receives FDA IDE Approval for Pivotal Study with ShortCut(TM) Device

Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based solutions for treating heart valves, announced today it received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to commence the ShortCut™ Pivotal Study, which will assess the safety and effectiveness of the ShortCut™ device.
Learn More

July 25, 2022

NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases

NewAmsterdam Pharma Holding B.V. (“Company”), a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, and Frazier Lifesciences Acquisition Corporation (“FLAC”), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners...
Learn More

February 8, 2021

Arcellx Announces Closing Of Initial Public Offering And Exercise In Full Of The Underwriters’ Option To Purchase Additional Shares

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the closing of its initial public offering of 9,487,500 shares of its common stock...
Learn More

December 20, 2021

Pi-Cardia ShortCut™ Device Successfully Treats First Patients in Europe

First Dedicated Device to Enable Coronary Access and Prevent Coronary Obstruction During TAVR.
Learn More

April 3, 2021

Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies

Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022.
Learn More

January 14, 2021

NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program

Naarden, the Netherlands, January 14, 2021 – NewAmsterdam Pharma (NAP), a clinical stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, today announced completion of a $196M (€160M) Series A funding round.
Learn More

August 18, 2020

ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing

ImmPACT Bio USA, Inc., a company founded in the FutuRx incubator located in Ness Ziona, Israel, developing novel cell therapies for treating cancer, today announced the closing of a US$ 18 million equity financing round. The financing included OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda Ventures, Inc., RM Global Partners (RMGP) BioPharma Investment Fund, Novartis Venture Fund, Bukwang Pharmaceutical, Hayan Health Networks, Inc., and JVC Investment Partners.
Learn More

May 18, 2020

UChicago Medicine gets $10 Million for Cancer Research

The gift from longtime health care executive David Jonas aims to improve emerging treatments that use the body's own immune system to fight the disease.
Learn More

April 20, 2020

Pi-Cardia Closes a $27 Million Financing led by Sofinnova Partners

Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, announced today it has closed a $27 million round of financing, led by Sofinnova Partners, a leading European life sciences venture capital firm, and joined by Professor Jacques Séguin, Chairman of the company, with further participation from existing investors.
Learn More

October 3, 2019

Arcellx Raises $85 Million in a Series B Financing to Advance its Intelligent Cell Therapy Program

Arcellx, a privately-held biopharmaceutical company, today announced that it has raised $85 million in an oversubscribed Series B financing. Proceeds will be used to advance the Company’s ARC-T + sparX programs, including clinical development of a bivalent BCMA-targeted cell therapy in multiple myeloma, and a CD123-targeted therapy in acute myeloid leukemia.
Learn More

July 29, 2019

Magenta Medical Closes Funding Round Led by NEA In Its First-Ever Life Sciences Investment in Israel

Magenta Medical, the developer of heart failure solutions based on proprietary miniaturized blood pump technology, today announced a financing round led by global venture capital firm New Enterprise Associates (NEA), with participation from existing investors, including Pitango Venture Capital, JVC Investment Partners and a group of private investors led by Prof. Jacques Seguin (CoreValve, ReCor).
Learn More

April 13, 2018

Novartis-AveXis Deal Could Be Game-Changer for Chicago

Chicago scored a major win April 9, but it barely registered with most local business leaders. The triumph was Novartis' eye-popping $8.7 billion buyout of a largely unknown startup called AveXis. It was far and away the biggest acquisition yet of a Chicago-area biotech company, more than three times the size of the next largest deal—the 2015 sale of Lake Forest-based PharMEDium to AmerisourceBergen for $2.58 billion.
Learn More

April 5, 2018

Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.

Chicago scored a major win April 9, but it barely registered with most local business leaders. The triumph was Novartis' eye-popping $8.7 billion buyout of a largely unknown startup called AveXis. It was far and away the biggest acquisition yet of a Chicago-area biotech company, more than three times the size of the next largest deal—the 2015 sale of Lake Forest-based PharMEDium to AmerisourceBergen for $2.58 billion.
Learn More

November 21, 2015

AmerisourceBergen to Buy PharMEDium for $2.58 Billion

David Jonas doesn't like to sit idle. He plays tennis, not golf. He's an early riser, often starting his day with a run of 4 to 5 miles on an empty stomach. When he retired from Baxter International after 25 years, he started a new company. It just sold for $2.58 billion.
Learn More

PharMEDium - LEK Consulting

L.E.K.’s CEO Stuart Jackson, discusses PharMEDium's extraordinary growth trajectory.
Learn More
Image
650 Dundee Road, Suite 380, Northbrook, IL 60062
P: 847.960.3840 | E: info@jvcmanagement.com

Investing our own capital in people with great vision, technologies and promise.

© JVC Investment Partners, All Rights Reserved.